Hallo! Tracked shipping to Netherlands with Delivery Duty Paid for just €7 

Ship to
Netherlands
0

My Account

  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional

menu

Select your country

Americas

Europe

Rest of the world

portada Resistance to Targeted Therapies in Lymphomas
Type
Physical Book
Publisher
Author
Language
English
Pages
210
Format
Hardcover
Dimensions
23.4x15.6x1.4 cm
Weight
0.50 kg.
ISBN13
9783030244231
Categories

Resistance to Targeted Therapies in Lymphomas

Xavier, Ana C. ; Cairo, Mitchell S. (Author) · Springer · Hardcover

Resistance to Targeted Therapies in Lymphomas - Xavier, Ana C. ; Cairo, Mitchell S.

Cheaper New Book Imported to Netherlands
Delivery: 12 Nov - 19 Nov Shipping: 14 to 18 business days.
€ 101,00
Faster New Book Imported to Netherlands
Delivery: 30 Oct - 03 Nov Shipping: 5 to 6 business days.
€ 136,13
Import costs and 9% BTW included in the price ✅
€ 101,00

Choose the list to add your product or create one New List

Go to My Wishlists
Calculate shipping cost

Synopsis "Resistance to Targeted Therapies in Lymphomas"

Over the past few decades, lymphoma patient outcomes have improved as a result of multidrug chemotherapy and radiation therapy, intensification of treatment, improvement in supportive care, and better imaging and staging systems. Even more recently, there has been tremendous progress in the understanding of cancer cell biology and its microenvironment which has resulted in the development of biologic agents, also called "target" therapies. These therapies are more specific in targeting cancer cells either directly or via enhancement of the immune system. Many clinical studies have focused on biological agents in combination with traditional chemotherapy with the goal of improved outcomes, or reduced acute long term complications that are associated with lymphoma therapy. This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but will also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era.

Customers reviews

More customer reviews
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)

Frequently Asked Questions about the Book

Is the book original?

All books in our catalog are Original.

In what language is the book written?

The book is written in English.

What is the format of this book?

The binding of this edition is Hardcover.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews